Anti-obesity effect of irreversible MAO-B inhibitors in patients with Parkinson’s disease

Anti-obesity effect of irreversible MAO-B inhibitors in patients with Parkinson’s disease

Abstract We read with great interest the report on the new anti-obesity potential in mice models of reversible monoamine oxidase B inhibitors by Moonsun et al., as opposed to the lack of such effects observed with irreversible MAO-B inhibitors (iMAO-Bi). Our research aimed to explore the potential a...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Siyu Liang, Yuxin Sun, Shi Chen, Hui Pan
Format:	Artykuł
Język:	English
Wydane:	Nature Publishing Group 2024-11-01
Seria:	Nutrition & Diabetes
Dostęp online:	https://doi.org/10.1038/s41387-024-00317-y

Podobne zapisy

Neuropsychiatrie disorders in Parkinson's disease and their correction with the MAO-B inhibitor rasagiline (Azilect®)
od: M. R. Nodel
Wydane: (2011-09-01)

Effects of combined MAO-B inhibitors and levodopa vs monotherapy in Parkinson’s disease
od: Rakhee eKrishna, i wsp.
Wydane: (2014-07-01)

Differences in CSF Biomarkers Profile of Patients with Parkinson's Disease Treated with MAO-B Inhibitors in Add-On
od: Henri Zenuni, i wsp.
Wydane: (2022-10-01)

Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disease
od: Pablo Duarte, i wsp.
Wydane: (2022-01-01)

Chemical space navigation by machine learning models for discovering selective MAO-B enzyme inhibitors for Parkinson’s disease
od: P. Catherene Tomy, i wsp.
Wydane: (2023-12-01)

Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: A systematic review
od: Takashi Tsuboi, i wsp.
Wydane: (2022-06-01)

Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson’s Disease
od: Xuebao Wang, i wsp.
Wydane: (2017-06-01)

MAO-B Polymorphism Associated with Progression in a Chinese Parkinson’s Disease Cohort but Not in the PPMI Cohort
od: Shi-Shuang Cui, i wsp.
Wydane: (2022-01-01)

Discovery of novel 2-(4-(benzyloxy)-5-(hydroxyl) phenyl) benzothiazole derivatives as multifunctional MAO-B inhibitors for the treatment of Parkinson’s disease
od: Zhongcheng Cao, i wsp.
Wydane: (2023-12-01)

MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology.
od: Jyothi K Mallajosyula, i wsp.
Wydane: (2008-02-01)

Computational exploration of acefylline derivatives as MAO-B inhibitors for Parkinson’s disease: insights from molecular docking, DFT, ADMET, and molecular dynamics approaches
od: Ali Irfan, i wsp.
Wydane: (2024-10-01)

In silico studies of natural product-like caffeine derivatives as potential MAO-B inhibitors/AA2AR antagonists for the treatment of Parkinson's disease
od: Boulaamane Yassir, i wsp.
Wydane: (2022-09-01)

Correction: MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
Wydane: (2012-01-01)

Antiparkinsonian activity of selective MAO-B inhibitors of different chemical structures
od: Vladimir N. Fedorov, i wsp.
Wydane: (2024-12-01)

Structure-Based Design of Novel MAO-B Inhibitors: A Review
od: Emilio Mateev, i wsp.
Wydane: (2023-06-01)

Irreversible tyrosine kinase inhibitors induce the endocytosis and downregulation of ErbB2
od: Chinmoy Ghosh, i wsp.
Wydane: (2023-07-01)

A Case of SSRI Induced Irreversible Parkinsonism
od: Siddharth Dixit, i wsp.
Wydane: (2015-02-01)

Development of a Novel Class of Pyridazinone Derivatives as Selective MAO-B Inhibitors
od: Mehmet Abdullah Alagöz, i wsp.
Wydane: (2022-06-01)

Computationally Assisted Lead Optimization of Novel Potent and Selective MAO-B Inhibitors
od: Vedanjali Gogineni, i wsp.
Wydane: (2021-09-01)

Novel Thiosemicarbazone Derivatives: In Vitro and In Silico Evaluation as Potential MAO-B Inhibitors
od: Derya Osmaniye, i wsp.
Wydane: (2021-11-01)

Coumarin-Chalcone Hybrids as Inhibitors of MAO-B: Biological Activity and In Silico Studies
od: Guillermo Moya-Alvarado, i wsp.
Wydane: (2021-04-01)

Design and Synthesis of New Benzothiazole Compounds as Selective hMAO-B Inhibitors
od: Sinem Ilgın, i wsp.
Wydane: (2017-12-01)

Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease
od: Scarlet eGallegos, i wsp.
Wydane: (2015-03-01)

“Click” assembly of novel dual inhibitors of AChE and MAO-B from pyridoxine derivatives for the treatment of Alzheimer’s disease
od: Jia Zhao, i wsp.
Wydane: (2022-02-01)

In Silico Evaluation and In Vitro Determination of Neuroprotective and MAO-B Inhibitory Effects of Pyrrole-Based Hydrazones: A Therapeutic Approach to Parkinson’s Disease
od: Magdalena Kondeva-Burdina, i wsp.
Wydane: (2022-12-01)

Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors
od: Caroline D. Binde, i wsp.
Wydane: (2021-01-01)

Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders
od: Payyalot Koyiparambath Vishal, i wsp.
Wydane: (2021-06-01)

Mao Mao : inside Gary's head
od: Chia, Gary Yew Hong
Wydane: (2019)

Are Terminal Alkynes Necessary for MAO-A/MAO-B Inhibition? A New Scaffold Is Revealed
od: Panagiou Mavroeidi, i wsp.
Wydane: (2024-05-01)

Study on the Neuroprotective, Radical-Scavenging and MAO-B Inhibiting Properties of New Benzimidazole Arylhydrazones as Potential Multi-Target Drugs for the Treatment of Parkinson’s Disease
od: Neda Anastassova, i wsp.
Wydane: (2022-04-01)

As mãos
od: Simone Christina Petry
Wydane: (2020-03-01)

The Antiproliferative Effects of Flavonoid MAO Inhibitors on Prostate Cancer Cells
od: Najla O. Zarmouh, i wsp.
Wydane: (2020-05-01)

Modification of Monoaminergic Activity by MAO Inhibitors Influences Methamphetamine Actions
od: Junichi Kitanaka, i wsp.
Wydane: (2006-01-01)

Modification of Monoaminergic Activity by MAO Inhibitors Influences Methamphetamine Actions
od: Junichi Kitanaka, i wsp.
Wydane: (2006-01-01)

Targeting MAO-B with Small-Molecule Inhibitors: A Decade of Advances in Anticancer Research (2012–2024)
od: Iyman Alsaad, i wsp.
Wydane: (2024-12-01)

High-throughput discovery of highly selective reversible hMAO-B inhibitors based on at-line nanofractionation
od: Yu Fan, i wsp.
Wydane: (2024-04-01)

The Up-Regulation of Oxidative Stress as a Potential Mechanism of Novel MAO-B Inhibitors for Glioblastoma Treatment
od: Guya Diletta Marconi, i wsp.
Wydane: (2019-05-01)

Mao Mao : chirping through Junyuan's ears
od: Loo, Jun Yuan
Wydane: (2019)

Selective and irreversible inhibitors of mosquito acetylcholinesterases for controlling malaria and other mosquito-borne diseases.
od: Yuan-Ping Pang, i wsp.
Wydane: (2009-08-01)

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors
od: Verbrugge Sue Ellen, i wsp.
Wydane: (2013-01-01)